Cardiomegaly pharmacotherapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 10: | Line 10: | ||
=== Chronic Pharmacotherapies === | === Chronic Pharmacotherapies === | ||
A combination of [[diuretic]]s and [[angiotensin converting enzyme]] ([[ACE]]) inhibition is currently the standard of care. [[Digoxin]] may reduce the frequency of rehospitalization, but does not improve mortality. | A combination of [[diuretic]]s and [[angiotensin converting enzyme]] ([[ACE]]) inhibition is currently the standard of care. [[Digoxin]] may reduce the frequency of rehospitalization, but does not improve mortality. | ||
== References == | == References == |
Revision as of 15:24, 26 July 2011
Cardiomegaly Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Cardiomegaly pharmacotherapy On the Web |
Directions to Hospitals Treating Cardiomegaly pharmacotherapy |
Risk calculators and risk factors for Cardiomegaly pharmacotherapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor in Chief: Cafer Zorkun, M.D., Ph.D. [2]
Pharmacotherapy
Acute Pharmacotherapies
- Administration of digoxin, diuretics, antiarrhythmics and/or preload and afterload reducers per clinical indication
Chronic Pharmacotherapies
A combination of diuretics and angiotensin converting enzyme (ACE) inhibition is currently the standard of care. Digoxin may reduce the frequency of rehospitalization, but does not improve mortality.